Literature DB >> 2422271

Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV.

T Folks, J Kelly, S Benn, A Kinter, J Justement, J Gold, R Redfield, K W Sell, A S Fauci.   

Abstract

Normal human peripheral blood lymphocytes were tested for their susceptibility to infection with retroviruses isolated from patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. Of 10 normal individuals tested, lymphocytes from all subjects became infected and produced virus as detected by assay for Mg+2-dependent reverse transcriptase. Lymphocytes from different individuals were demonstrated to be either high or low producers of reverse transcriptase after infection. The kinetics of virus production were similar in cells from both high- and low-producing individuals. A significant correlation was observed between high and low viral-producing lymphocytes and expression of the Leu-3/T4 (CD4) surface molecule. Mitogen-stimulated peripheral blood lymphocytes exposed to HTLV-III/LAV manifested productive viral infection, as reflected by the appearance of early syncytia, followed by reverse transcriptase. Unstimulated peripheral blood lymphocyte cultures displayed late syncytia but no detectable reverse transcriptase upon exposure to virus. The addition of anti-human interferon-alpha did not appear to have an appreciable effect on viral production in normal peripheral blood lymphocytes exposed to the virus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422271

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity.

Authors:  S Nekhai; R R Shukla; A Kumar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  The intragenic enhancer of human immunodeficiency virus type 1 contains functional AP-1 binding sites.

Authors:  C Van Lint; A Burny; E Verdin
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

Review 3.  Targeting anti-HIV drugs to the CNS.

Authors:  Kavitha S Rao; Anuja Ghorpade; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

4.  NF-IL6 (C/EBPbeta) induces HIV-1 replication by inhibiting cytidine deaminase APOBEC3G.

Authors:  Shigemi M Kinoshita; Shizuka Taguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

5.  Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.

Authors:  J Y Zhou; D C Montefiori
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.

Authors:  W A Scott; D Brambilla; E Siwak; C Beatty; J Bremer; R W Coombs; H Farzadegan; S A Fiscus; S M Hammer; F B Hollinger; N Khan; S Rasheed; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

7.  Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells.

Authors:  B A Castro; C D Weiss; L D Wiviott; J A Levy
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

8.  Identification and characterization of an enhancer in the coding region of the genome of human immunodeficiency virus type 1.

Authors:  E Verdin; N Becker; F Bex; L Droogmans; A Burny
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

9.  Thalidomide inhibits the replication of human immunodeficiency virus type 1.

Authors:  S Makonkawkeyoon; R N Limson-Pobre; A L Moreira; V Schauf; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  CpG methylation controls reactivation of HIV from latency.

Authors:  Jana Blazkova; Katerina Trejbalova; Françoise Gondois-Rey; Philippe Halfon; Patrick Philibert; Allan Guiguen; Eric Verdin; Daniel Olive; Carine Van Lint; Jiri Hejnar; Ivan Hirsch
Journal:  PLoS Pathog       Date:  2009-08-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.